Key Takeaways & Executive Findings
- •• Natural products remain a rich source of anticancer leads, with several compounds in clinical trials targeting novel pathways. • Advanced screening and AI-driven approaches are significantly accelerating the discovery of bioactive natural compounds. • Combination therapies using natural products can help overcome multidrug resistance in cancer cells. • Sustainable sourcing and synthetic biology are critical for ensuring the future availability of promising natural product drugs.
Abstract
Natural products have long been a vital source of anticancer agents, with numerous clinically approved drugs derived from plants, marine organisms, and microorganisms. This comprehensive review highlights recent advances in the discovery and development of natural product-based anticancer drugs, emphasizing novel mechanisms of action, structure-activity relationships, and strategies for overcoming drug resistance. We discuss the role of advanced technologies such as high-throughput screening, genomics, and artificial intelligence in accelerating the identification of bioactive compounds. Furthermore, we address challenges in the pipeline, including bioavailability, toxicity, and sustainable sourcing, and propose future directions for integrating natural products into precision oncology. Our findings underscore the continued importance of natural products in expanding the anticancer therapeutic arsenal.
1. Introduction
Cancer remains one of the leading causes of mortality worldwide, driving an urgent need for novel therapeutic agents. Natural products, derived from plants, marine organisms, and microbes, have historically been a cornerstone of anticancer drug discovery, with examples such as paclitaxel, doxorubicin, and vincristine. Despite the rise of synthetic chemistry and targeted therapies, natural products continue to offer unparalleled chemical diversity and biological relevance, making them an invaluable resource for identifying new drug candidates.
In recent years, technological advancements have revolutionized the field, enabling more efficient screening of natural product libraries, elucidation of mechanisms of action, and optimization of lead compounds. This review aims to provide a comprehensive overview of the latest developments in natural product-based anticancer drug discovery, highlighting key successes, ongoing challenges, and future opportunities in the context of precision medicine.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, X. Liu, H. Chen (2026). Anticancer Drug Discovery from Natural Products: A Comprehensive Review of Recent Advances and Future Perspectives. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are the main sources of natural product anticancer drugs?
Natural product anticancer drugs are derived from plants (e.g., paclitaxel from yew trees), marine organisms (e.g., trabectedin from sea squirts), and microorganisms (e.g., doxorubicin from Streptomyces). These sources provide diverse chemical structures that can target cancer cells through various mechanisms.
How do natural products help overcome drug resistance in cancer?
Natural products can overcome drug resistance by acting on multiple molecular targets, inhibiting efflux pumps like P-glycoprotein, and modulating signaling pathways that contribute to resistance. Combination therapies with natural products have shown promise in resensitizing resistant cancer cells.
What role does artificial intelligence play in natural product drug discovery?
Artificial intelligence (AI) accelerates drug discovery by predicting the bioactivity of natural compounds, optimizing lead structures, and identifying potential targets. Machine learning models can screen vast libraries of natural products in silico, reducing time and cost.
What are the challenges in developing natural product anticancer drugs?
Challenges include low bioavailability, potential toxicity, complex synthesis, and sustainable sourcing. Many natural products are present in small quantities in their sources, making large-scale production difficult. Advances in synthetic biology and total synthesis are addressing these issues.
What is the future outlook for natural products in cancer therapy?
The future is promising, with integration of natural products into precision oncology, combination therapies, and novel drug delivery systems. Continued exploration of untapped biodiversity and collaborative efforts between academia and industry will likely yield new anticancer agents.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.